Schistosoma infection is associated with immune modulation that can influence responses to non-schistosome antigens. Vaccine responses may be impaired in S. mansoni-infected individuals. We investigated effects of S. mansoni infection on responses to childhood measles catch-up immunisation and of praziquantel treatment on this outcome in a randomised trial. The Immune Modulation and Childhood Immunisation (IMoChI) study was based in Entebbe, Uganda. Children aged 3–5 years (193 S. mansoni-infected and 61 uninfected) were enrolled. Infected children were randomised in a 1:1:1 ratio to receive praziquantel 2 weeks before, at time of, or 1 week after, measles catch-up immunisation. Plasma anti-measles IgG was measured at enrolment, 1 week and 24 weeks after measles immunisation. Primary outcomes were IgG levels and percentage of participants with levels considered protective against measles. Anti-measles IgG levels increased following immunisation, but at 1 week post-immunisation S. mansoni-infected, compared to uninfected, children had lower levels of anti-measles IgG (adjusted geometric mean ratio (aGMR) 0.4 [95% CI 0.2–0.7]) and the percentage with protective antibody levels was also lower (adjusted odds ratio 0.1 [0–0.9]). Among S. mansoni-infected children, anti-measles IgG one week post-immunisation was higher among those treated with praziquantel than among those who were not yet treated (treatment before immunisation, aGMR 2.3 [1.5–4.8]; treatment at immunisation aGMR 1.8 [1.1–3.5]). At 24 weeks post-immunisation, IgG levels did not differ between the trial groups, but tended to be lower among previously-infected children who were still S mansoni stool-positive than among those who became stool-negative. Our findings suggest that S. mansoni infection among pre-school children is associated with a reduced antibody response to catch-up measles immunisation, and that praziquantel treatment improves the response. S. mansoni infection may contribute to impaired vaccine responses in endemic populations; effective schistosomiasis control may be beneficial for vaccine efficacy. This should be further explored. ISRCTN87107592. Infection with the blood fluke Schistosoma mansoni, which causes Bilharzia, is common among communities living along the shores of Lake Victoria in Uganda and elsewhere around fresh water bodies in Africa. Infection with this parasite is known to alter the body’s immune responses, even to stimuli which are not directly related to the parasite. This alteration may have an adverse impact on responses to vaccines. However, there is still insufficient information on such effects and on whether treatment of schistosomiasis can reverse them. We conducted a study on the Entebbe peninsula in Lake Victoria to examine the effects of infection with S. mansoni parasites on responses to childhood measles catch-up immunisation, and the effect of treating the parasites on the responses. A cohort of 3–5 year-old children, either infected with S. mansoni or not, was enrolled and given measles immunisation. The infected children were treated for S. mansoni either before, at the time of, or a week after the immunisation. Levels of antibodies against measles were measured at one week and 24 weeks after immunisation as indicator of possible protection against measles. The levels of antibodies against measles were lower among the S mansoni-infected children than the uninfected children, and treatment improved this situation. This implies that S. mansoni infection is associated with reduced measles immunisation responses and that treatment improves the response. At 24 weeks post-immunisation, when all children had been treated for S. mansoni, at least 95% of children in all groups had protective levels of antibody. Considering that pre-school children are vulnerable to Bilharzia, an effective schistosomiasis control programme that includes this age group may be beneficial for vaccine efficacy, an issue that needs further investigation.